B. Mennecier

4.1k total citations
75 papers, 1.4k citations indexed

About

B. Mennecier is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, B. Mennecier has authored 75 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pulmonary and Respiratory Medicine, 45 papers in Oncology and 13 papers in Epidemiology. Recurrent topics in B. Mennecier's work include Lung Cancer Treatments and Mutations (46 papers), Colorectal Cancer Treatments and Studies (19 papers) and Lung Cancer Research Studies (18 papers). B. Mennecier is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Colorectal Cancer Treatments and Studies (19 papers) and Lung Cancer Research Studies (18 papers). B. Mennecier collaborates with scholars based in France, United States and Poland. B. Mennecier's co-authors include Romain Kessler, M Faller, E Weitzenblum, Élisabeth Quoix, Wolfgang Pfeifer, Rodryg Ramlau, Manuel Constenla, A. Szczęsna, Rafael Rosell and Michèle Beau‐Faller and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

B. Mennecier

71 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Mennecier France 15 1.1k 663 241 118 100 75 1.4k
Gabriel Boldt Canada 18 950 0.9× 571 0.9× 75 0.3× 94 0.8× 76 0.8× 89 1.5k
Timothy R. Asmis Canada 19 420 0.4× 758 1.1× 258 1.1× 212 1.8× 208 2.1× 66 1.3k
Osamu Hataji Japan 17 734 0.7× 281 0.4× 143 0.6× 80 0.7× 99 1.0× 73 1.2k
Motohiro Yamashita Japan 21 1.2k 1.1× 372 0.6× 161 0.7× 98 0.8× 189 1.9× 84 1.7k
Yuki Sato Japan 21 801 0.7× 834 1.3× 123 0.5× 80 0.7× 93 0.9× 108 1.5k
Joaquín Montalar Spain 15 543 0.5× 606 0.9× 201 0.8× 77 0.7× 145 1.4× 41 959
Leila T. Tchelebi United States 14 363 0.3× 434 0.7× 194 0.8× 144 1.2× 186 1.9× 45 1.0k
Fatma Şen Türkiye 18 318 0.3× 488 0.7× 127 0.5× 110 0.9× 162 1.6× 73 1.0k
Vanita Noronha India 16 404 0.4× 456 0.7× 148 0.6× 66 0.6× 120 1.2× 97 1.0k
Bala Başak Öven Ustaalıoğlu Türkiye 16 433 0.4× 523 0.8× 107 0.4× 121 1.0× 177 1.8× 83 1.1k

Countries citing papers authored by B. Mennecier

Since Specialization
Citations

This map shows the geographic impact of B. Mennecier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Mennecier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Mennecier more than expected).

Fields of papers citing papers by B. Mennecier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Mennecier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Mennecier. The network helps show where B. Mennecier may publish in the future.

Co-authorship network of co-authors of B. Mennecier

This figure shows the co-authorship network connecting the top 25 collaborators of B. Mennecier. A scholar is included among the top collaborators of B. Mennecier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Mennecier. B. Mennecier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bahougne, Thibault, Philippe Barthélémy, Lionnel Geoffrois, et al.. (2024). Central nervous system complications of immune checkpoint inhibitors: A comprehensive review. Critical Reviews in Oncology/Hematology. 206. 104595–104595. 7 indexed citations
2.
Mennecier, B., Jonathan Khalifa, R. Descourt, et al.. (2024). Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study. BMC Cancer. 24(1). 421–421. 2 indexed citations
3.
4.
Baldacci, Simon, Benjamin Besse, Virginie Avrillon, et al.. (2020). 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Annals of Oncology. 31. S843–S843. 1 indexed citations
5.
6.
Bender, Laura, et al.. (2019). Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report. Annals of Translational Medicine. 7(5). 106–106. 11 indexed citations
7.
Antoine, Martine, Denis Moro‐Sibilot, C. Dayen, et al.. (2018). Inhibiteurs du check-point immunitaire en néo-adjuvant dans les cancers bronchiques non à petites cellules localisés : essai IoNESCO. Revue des Maladies Respiratoires. 35(9). 983–988. 11 indexed citations
8.
Dansin, Éric, Laurent Mhanna, Laurent Greillier, et al.. (2018). Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. Journal of Thoracic Oncology. 13(11). 1762–1770. 50 indexed citations
9.
Leduc, Charlotte, Nathalie Prim, B. Mennecier, et al.. (2016). Diagnosis of Jejunal Metastases from Lung Cancer Using Capsule Endoscopy. Case Reports in Oncology. 9(3). 526–529. 5 indexed citations
10.
Sassier, Marion, B. Mennecier, Antoine Coquerel, et al.. (2016). Successful treatment with ceritinib after crizotinib induced hepatitis. Lung Cancer. 95. 15–16. 12 indexed citations
11.
Collongues, Nicolas, et al.. (2014). Utilisation d’une banque de données auscultatoires : vers une école de l’auscultation. 20(2). 87–92. 1 indexed citations
12.
Girard, Nicolas, Clarisse Audigier-Valette, Alexis B. Cortot, et al.. (2014). ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?. Expert Review of Anticancer Therapy. 15(2). 225–233. 9 indexed citations
13.
Dansin, Éric, Sophie Cousin, Géraldine Lauridant, & B. Mennecier. (2013). Bévacizumab en oncologie thoracique : résultats et aspects pratiques. Revue de Pneumologie Clinique. 69(3). 159–169. 1 indexed citations
14.
Mennecier, B., et al.. (2010). Métastases musculaires de cancers bronchiques : à propos de sept cas. Revue de Pneumologie Clinique. 67(2). 75–81. 3 indexed citations
15.
Antoni, D., Mi‐Young Jeung, B. Mennecier, et al.. (2009). A Two-Faced Young Woman. Journal of Thoracic Oncology. 4(2). 240–241. 1 indexed citations
16.
Spaëth, Dominique, B Desablens, Philippe Rodon, et al.. (2008). Epoetin β Once-Weekly Therapy in Anemic Patients with Solid Tumors and Non-Myeloid Hematological Malignancies Receiving Chemotherapy. Oncology. 74(1-2). 112–118. 5 indexed citations
17.
Mennecier, B., et al.. (2004). Anomalies de la coagulation et événements thromboemboliques artériels dans le cancer bronchique non à petites cellules. Revue de Pneumologie Clinique. 60(3). 175–179. 2 indexed citations
18.
Quoix, Élisabeth & B. Mennecier. (2003). Cancer du poumon et pollution.. Revue de Pneumologie Clinique. 59(4). 2 indexed citations
19.
Mennecier, B., Marie-Paule Lebitasy, L. Moreau, et al.. (2003). Women and small cell lung cancer: social characteristics, medical history, management and survival. Lung Cancer. 42(2). 141–152. 18 indexed citations
20.
Kessler, Romain, et al.. (1999). Predictive Factors of Hospitalization for Acute Exacerbation in a Series of 64 Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 159(1). 158–164. 395 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabriel Boldt Breakdown of academic impact, for papers by Timothy R. Asmis Breakdown of academic impact, for papers by Osamu Hataji Breakdown of academic impact, for papers by Motohiro Yamashita Breakdown of academic impact, for papers by Yuki Sato Breakdown of academic impact, for papers by Joaquín Montalar Breakdown of academic impact, for papers by Leila T. Tchelebi Breakdown of academic impact, for papers by Fatma Şen Breakdown of academic impact, for papers by Vanita Noronha Breakdown of academic impact, for papers by Bala Başak Öven Ustaalıoğlu
Rankless by CCL
2026